Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Multiple Sclerosis

Free Subscription 25.08.2025 1 AJNR Am J Neuroradiol 1 Arch Phys Med Rehabil 2 Brain 1 J Neuroimmunol 9 J Neurol 1 J Neurol Sci 4 Mult Scler 1 Nat Med

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJNR Am J Neuroradiol

1. BARBUTI E, Conti A, Treaba CA, Miscioscia A, et al
   Choroid Plexus Enlargement in Multiple Sclerosis Correlates with Cortical and Phase Rim lesions on 7-T MRI and Predicts Progression Independent of Relapse Activity.
   AJNR Am J Neuroradiol. 2025 Aug 25:ajnr.A8983. doi: 10.3174/ajnr.A8983.
   PubMed         Abstract available
   
   

   
   Arch Phys Med Rehabil

2. KIM J, Ehde DM, Alschuler KN, Fritz NE, et al
   Temporal Association Between Reported Use of Psychoactive Substances and Cognitive Function in People with Multiple Sclerosis.
   Arch Phys Med Rehabil. 2025 Aug 19:S0003-9993(25)00854.
   PubMed         Abstract available
   
   

   
   Brain

3. PAPE K, Hanuscheck N, Schmaul S, Kneilmann F, et al
   Role of CD5 signalling for pro-inflammatory Th17 response in multiple sclerosis.
   Brain. 2025 Aug 25:awaf268. doi: 10.1093.
   PubMed         Abstract available
   
   
4. RODRIGUES P, Frare JM, Ruviaro NA, Peres DS, et al
   Advanced oxidation protein products activated TRPA1 in a neuropathic multiple sclerosis model.
   Brain. 2025 Aug 17:awaf306. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Neuroimmunol

5. SAXENA S, Zhirova A, Krishnan R, Healy B, et al
   SARS-CoV-2 spike antibody and T cell response in MS patients on high efficacy therapies post vaccine.
   J Neuroimmunol. 2025;407:578694.
   PubMed         Abstract available
   
   

   
   J Neurol

6. ALFREDSSON L, Guo J, Johansson E, Olsson T, et al
   Early-life and adult body mass index in relation to MS disability progression.
   J Neurol. 2025;272:571.
   PubMed         Abstract available
   
   
7. SBAIHAT H, Roenneke K, Muller D, Ladopoulos T, et al
   MRI-based human brain atlases of R1, R2, proton density, and myelin volume fraction using synthetic quantitative imaging at 1.5 T.
   J Neurol. 2025;272:578.
   PubMed         Abstract available
   
   
8. JAWORSKI M 3RD, Balconi J, Santivasci C, Youngs M, et al
   Improving conscientiousness through a smartphone app and telecoaching intervention: insights from multiple sclerosis and healthy aging samples.
   J Neurol. 2025;272:580.
   PubMed         Abstract available
   
   
9. ABBADESSA G, Maida E, Bonavita S, Lavorgna L, et al
   First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis.
   J Neurol. 2025;272:582.
   PubMed         Abstract available
   
   
10. GUERRIERI S, Gattuso I, Genchi A, Nozzolillo A, et al
    Stratify and ImmunoWELL JCV tests performances in a real-world multiple sclerosis cohort: possible clinical implications of biosimilar Natalizumab use.
    J Neurol. 2025;272:583.
    PubMed        
    
    
11. SCANDIFFIO J, Langer LK, Senthilnathan V, Feng G, et al
    Effects of psychological therapies in people with multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials.
    J Neurol. 2025;272:584.
    PubMed         Abstract available
    
    
12. REEVES JA, Tranquille A, Bartnik A, Mohebbi M, et al
    Paramagnetic rim lesions are associated with choroid plexus inflammation and expansion over 5 years in people with multiple sclerosis.
    J Neurol. 2025;272:585.
    PubMed         Abstract available
    
    
13. ADAMMEK F, Gralla W, Kupjetz M, Rademacher A, et al
    Functional exercise training in persons with multiple sclerosis: a systematic review.
    J Neurol. 2025;272:590.
    PubMed         Abstract available
    
    
14. MATHEY G, Epstein J, Alix T, Julien M, et al
    Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.
    J Neurol. 2025;272:592.
    PubMed         Abstract available
    
    

    
    J Neurol Sci

15. LADAKIS DC, Ghajarzadeh M, Bhargava P, Absinta M, et al
    Association of paramagnetic rim lesions with patient-reported neuropsychiatric symptoms in multiple sclerosis.
    J Neurol Sci. 2025;477:123657.
    PubMed         Abstract available
    
    

    
    Mult Scler

16. BRIGGS FB, Genuario I, De Nadai AS, Gunzler DD, et al
    Predicting suicidal ideation at subsequent clinical encounter in multiple sclerosis patients.
    Mult Scler. 2025 Aug 25:13524585251365207. doi: 10.1177/13524585251365207.
    PubMed         Abstract available
    
    
17. ZHAO DH, Hadley G, Pisa M, Saunders P, et al
    Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage.
    Mult Scler. 2025 Aug 20:13524585251365791. doi: 10.1177/13524585251365791.
    PubMed         Abstract available
    
    
18. KRAJNC N, Ponleitner M, Fottinger F, Leutmezer F, et al
    Serum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosis.
    Mult Scler. 2025 Aug 19:13524585251360972. doi: 10.1177/13524585251360972.
    PubMed         Abstract available
    
    
19. JOKUBAITIS VG, Alroughani R, Altintas A, Eichau S, et al
    Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).
    Mult Scler. 2025;31:1088-1101.
    PubMed         Abstract available
    
    

    
    Nat Med

20. GANJGAHI H, Haring DA, Aarden P, Graham G, et al
    AI-driven reclassification of multiple sclerosis progression.
    Nat Med. 2025 Aug 20. doi: 10.1038/s41591-025-03901.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.